His primary scientific interests are in Nuclear medicine, Positron emission tomography, Radiology, Internal medicine and Blood flow. His study on Pet imaging is often connected to Comparison study as part of broader study in Nuclear medicine. The concepts of his Positron emission tomography study are interwoven with issues in Pathology, Histopathology and Cancer.
His research integrates issues of Lung cancer and Breast cancer in his study of Radiology. His work deals with themes such as Endocrinology, Oncology, Isoflurane, Cardiology and Xylazine, which intersect with Internal medicine. His Blood flow study integrates concerns from other disciplines, such as Hemodynamics, Anesthesia, Circulatory system and Vasodilation.
The scientist’s investigation covers issues in Nuclear medicine, Positron emission tomography, Radiology, PET-CT and Internal medicine. His Nuclear medicine research incorporates themes from Tomography, Biodistribution and Histopathology. His Positron emission tomography research includes elements of Cancer, Magnetic resonance imaging, Molecular imaging and Pathology.
Johannes Czernin has researched Radiology in several fields, including Neoadjuvant therapy, Breast cancer, Lymph node and Stage. His work in PET-CT tackles topics such as Prostate cancer which are related to areas like Cancer research and Radionuclide therapy. In the field of Internal medicine, his study on Clinical trial overlaps with subjects such as In patient.
Johannes Czernin mostly deals with Prostate cancer, PET-CT, Nuclear medicine, Radiology and Internal medicine. His biological study spans a wide range of topics, including Positron emission tomography, Cancer research and Prospective cohort study. His Positron emission tomography research is multidisciplinary, incorporating perspectives in Glutamate carboxypeptidase II and Psma pet.
His study brings together the fields of Biodistribution and Nuclear medicine. His Radiology study combines topics in areas such as Androgen deprivation therapy, Randomized controlled trial, Management of prostate cancer and Histopathology. His biological study deals with issues like Oncology, which deal with fields such as Castrate-resistant prostate cancer, Phases of clinical research and Cancer.
Johannes Czernin focuses on Prostate cancer, PET-CT, Radiology, Nuclear medicine and Biochemical recurrence. His Prostate cancer study is associated with Internal medicine. His PET-CT research incorporates elements of Urology, Molecular imaging, Repeatability, Cardiac imaging and Prospective cohort study.
Johannes Czernin combines subjects such as Positron emission tomography, Prior Primary, Glutamate carboxypeptidase II and Disease with his study of Urology. Johannes Czernin interconnects Esophagectomy, Esophageal cancer, 68Ga-PSMA-11 and Histopathology in the investigation of issues within Radiology. His research in Nuclear medicine is mostly concerned with Dosimetry.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Tabulated Summary of the FDG PET Literature
Sanjiv S. Gambhir;Johannes Czernin;Judy Schwimmer;Daniel H. S. Silverman.
The Journal of Nuclear Medicine (2001)
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
Daniel H. S. Silverman;Gary W. Small;Carol Y. Chang;Carolyn S. Lu.
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
George V Thomas;Chris Tran;Ingo K Mellinghoff;Derek S Welsbie.
Nature Medicine (2006)
Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction
Marcelo F. Di Carli;Michael Davidson;Roderick Little;Sandeep Khanna.
American Journal of Cardiology (1994)
A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer.
Ralf H. Huebner;Kenneth C. Park;James E. Shepherd;Judy Schwimmer.
The Journal of Nuclear Medicine (2000)
Influence of age and hemodynamics on myocardial blood flow and flow reserve.
J. Czernin;P. Müller;Sammy Chan;R. C. Brunken.
LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
David B. Shackelford;David B. Shackelford;Evan Abt;Laurie Gerken;Debbie S. Vasquez.
Cancer Cell (2013)
Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG
Wei Chen;Timothy Cloughesy;Nirav Kamdar;Nagichettiar Satyamurthy.
The Journal of Nuclear Medicine (2005)
Impact of Animal Handling on the Results of 18F-FDG PET Studies in Mice
Barbara J. Fueger;Johannes Czernin;Isabel Hildebrandt;Chris Tran.
The Journal of Nuclear Medicine (2006)
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
Wei Chen;Sibylle Delaloye;Daniel H.S. Silverman;Cheri Geist.
Journal of Clinical Oncology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: